Emergent Biosolutions Operating Income 2010-2022 | EBS

Emergent Biosolutions operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Emergent Biosolutions Annual Operating Income
(Millions of US $)
2021 $353
2020 $434
2019 $114
2018 $90
2017 $124
2016 $106
2015 $142
2014 $89
2013 $43
2012 $30
2011 $32
2010 $74
2009 $40
Emergent Biosolutions Quarterly Operating Income
(Millions of US $)
2022-03-31 $6
2021-12-31 $277
2021-09-30 $-35
2021-06-30 $15
2021-03-31 $95
2020-12-31 $258
2020-09-30 $61
2020-06-30 $126
2020-03-31 $-12
2019-12-31 $78
2019-09-30 $71
2019-06-30 $-7
2019-03-31 $-27
2018-12-31 $11
2018-09-30 $21
2018-06-30 $67
2018-03-31 $-10
2017-12-31 $53
2017-09-30 $48
2017-06-30 $9
2017-03-31 $15
2016-12-31 $51
2016-09-30 $35
2016-06-30 $-2
2016-03-31 $21
2015-12-31 $85
2015-09-30 $63
2015-06-30 $21
2015-03-31 $-28
2014-12-31 $76
2014-09-30 $31
2014-06-30 $8
2014-03-31 $-25
2013-12-31 $23
2013-09-30 $18
2013-06-30 $15
2013-03-31 $-13
2012-12-31 $24
2012-09-30 $10
2012-06-30 $9
2012-03-31 $-13
2011-12-31 $46
2011-09-30 $1
2011-06-30 $20
2011-03-31 $-36
2010-12-31 $35
2010-09-30 $21
2010-06-30 $15
2010-03-31 $3
2009-12-31 $4
2009-09-30 $-4
2009-06-30 $23
2009-03-31 $17
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.625B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00